A daily pill called orforglipron has won FDA approval and recent studies report it can blunt the rebound many patients experience after stopping injections. For readers, the clinical promise raises practical questions about cost, side effects, and who will have access to follow-up care. Those are the conversations clinicians, insurers, and communities need to have now to ensure treatments support lasting gains for more people.
Curious about how a tablet can influence the same appetite and metabolism pathways targeted by injections, and what that means for fairness in treatment? The full study digs into mechanism, trial results, and who was included in the research. Follow the link to see how this development might reshape options for maintaining weight loss and broadening access to lasting health improvements.
A new FDA-approved daily pill could help people coming off pricey weight-loss injections retain their weight loss, latest research says. Research found that patients given the tablet, called orforglipron, every day for a year avoided regaining much of the weight they had…
